Aya, FranciscoGonzález Navarro, E. AzucenaMartínez, Clara M.Carcelero, EstherArance, Ana2021-07-142021Aya F, González-Navarro EA, Martínez C, Carcelero E, Arance A. Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. Immunotherapy. 2021;13(9):745-52. DOI: 10.2217/imt-2020-02741750-743Xhttp://hdl.handle.net/10230/48176Aim: To evaluate the safety of rechallenge with a different anti-PD-1 antibody after an immune-related adverse event (irAE) that has prompted the discontinuation of anti-PD-1 therapy. Patients & methods: We describe two patients with metastatic melanoma who developed potentially disabling and early irAEs following anti-PD-1 treatment. Therapy was discontinued and toxicities resolved with corticosteroids. Results: Rechallenge switching to an alternative anti-PD-1 antibody did not lead to a new or recurrent irAE. Conclusion: Switching to a different anti-PD-1 antibody when resuming therapy after an irAE might be a safe strategy and warrants further investigation. Structural and biological differences between antibodies might explain the different safety outcomes.application/pdfeng© 2021 Future Medicine Ltdinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.2217/imt-2020-0274Anti-PD-1AntibodyImmune checkpoint inhibitorsImmune-related adverse eventImmunotherapyMelanomaRechallengeSwitching antibodiesToxicityinfo:eu-repo/semantics/openAccess